Nonobese Population in a Developing Country Has a High Prevalence of Nonalcoholic Fatty Liver and Significant Liver Disease

Kausik Das,[1] Kshaunish Das,[2] Partha S. Mukherjee,[5] Alip Ghosh,[4] Sumantra Ghosh,[4] Asit R. Mridha,[3] Tapan Dhibar,[6] Bhaskar Bhattacharya,[6] Dilip Bhattacharya,[1] Byomkesh Manna,[7] Gopal K. Dhali,[2] Amal Santra,[4] and Abhijit Chowdhury[1,5]

There is a paucity of community-based epidemiological data on nonalcoholic fatty liver (NAFL) among nonaffluent populations in developing countries. Available studies are radiological and/or biochemical and lack histological assessment, limiting their strength. We conducted a prospective epidemiological study comprising a 1:3 subsample of all adult (>18 years) inhabitants of a rural administrative unit of West Bengal, India. Subjects positive for hepatitis B virus and/or hepatitis C virus infection and consuming any amount of alcohol were excluded. Diagnosis of NAFL was by dual radiological screening protocol consisting of ultrasonographic and computed tomographic examination of the liver. Transient elastographic examination and liver biopsy were performed in a subset to identify significant liver disease. The risk factors of having NAFL were analyzed. A total of 1,911 individuals were analyzed, 7% of whom were overweight and 11% of whom had abdominal obesity. The prevalence of NAFL, NAFL with elevated alanine aminotransferase, and cryptogenic cirrhosis was 8.7%, 2.3%, and 0.2%, respectively. Seventy-five percent of NAFL subjects had a body mass index (BMI) <25 kg/m^2, and 54% were neither overweight nor had abdominal obesity. The subjects with the highest risk of having NAFL were those with a BMI >25 kg/m^2 (odds ratio 4.3, 95% confidence interval 1.6-11.5). Abdominal obesity, dysglycemia (fasting plasma glucose >100 mg/dL or elevated homeostatic model assessment of insulin resistance), and higher income were the other risk factors. Even having a normal BMI (18.5-24.9 kg/m^2) was associated with a 2-fold increased risk of NAFL versus those with a BMI <18.5 kg/m^2. *Conclusion:* There is a significant prevalence of NAFL and potentially significant liver disease, including cryptogenic cirrhosis, in this predominantly nonobese, nonaffluent population in a developing country. NAFL will be a major determinant of future liver disease burden in countries of the developing world. (HEPATOLOGY 2010;51:1593-1602)

See Editorial on Page 1491.

Cirrhosis of the liver ranked as the thirteenth most common cause of mortality worldwide toward the end of the last decade.[1] Chronic viral hepatitis due to hepatitis B virus (HBV) and hepatitis C virus (HCV) is the most common cause of cirrhosis and hepatocellular carcinoma in developing countries.[2] Epidemiological studies on liver disease in developing countries have focused mostly on viral hepatitis.[3,4] This pattern is different from that seen in the developed nations of the West, where nonalcoholic fatty liver disease (NAFLD) ranks next only to HCV infection and alcoholism as the third most commonly diagnosed liver disease at United

Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; CI, confidence interval; CT, computed tomography; FPG, fasting plasma glucose; HBV, hepatitis B virus; HCV, hepatitis C virus; HOMA-IR, homeostatic model assessment of insulin resistance; IR, insulin resistance; LSM, liver stiffness measure; MS, metabolic syndrome; NAFL, nonalcoholic fatty liver; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; OR, odds ratio; SD, standard deviation.

From the Divisions of [1]Hepatology; [2]Gastroenterology, and [3]Pathology and [4]Center for Liver Research, School of Digestive and Liver Diseases, Institute of Postgraduate Medical Education and Research, Kolkata, India; [5]Liver Foundation, West Bengal, India; the [6]Department of Radiodiagnosis, Bangur Institute of Neurosciences and Psychiatry, Kolkata, India; and [7]National Institute of Cholera and Enteric Diseases, Kolkata, India.

Received September 5, 2009; accepted January 5, 2010.

Supported by Grant 844(Sanc)/ST/P/S&T/9G-8/2006 from the Department of Science and Technology, Government of West Bengal, India.

States gastroenterology practices.[5] The scenario is changing in developing countries, where an upward trend in the prevalence of noncommunicable diseases is evident as a result of economic prosperity and changes in sociodemographics and lifestyle.[6,7] Characterstically, many of these emerging public health priorities are clinical expressions of the metabolic syndrome (MS) and insulin resistance (IR).[6-8]

NAFLD, which is considered to be the hepatic manifestation of MS,[8] is a distinct clinico-pathologic entity characterized histologically by a spectrum ranging from bland steatosis to steatohepatitis and cirrhosis and even hepatocellular carcinoma.[9] Recent studies have indicated that the prevalence of NAFLD is fairly significant in Asian countries.[10] However, these studies have focused largely on economically developed segments of populations in these regions.[11,12] The prevalence of obesity and diabetes is rising in developing countries,[13] further underscoring the need for in-depth assessment of NAFLD epidemiology in these countries.

In general, there is limited epidemiological data on the prevalence of nonalcoholic fatty liver (NAFL) in the general population, even from the West.[14,15] Inconsistency in methodological designs to detect NAFL, heterogeneity of the population analyzed, and exclusion of liver biopsy in the assessment of a disease that is primarily defined histologically are some of the drawbacks of available studies.[11,12,14,15]

To define the prevalence and identify the risk factors of NAFL and significant liver disease in a developing country, we undertook a community-based study in a defined rural population from the Birbhum District, West Bengal, India.

Subjects and Methods

Population Sample. Adult (>18 years) inhabitants of Nagari Gram Panchayat in the Birbhum District of West Bengal, India, were included. A Gram Panchayat is the most peripheral rural administrative unit in India and comprises several villages in the vicinity. We purposely chose the village unit in the present study based on the framework of our previous population-based epidemiological work on HBV and HCV infection.[16,17] The voters list, an independent list of all adult eligible voters prepared by the Election Commission of India, updated 9 months prior to the study initiation, was used as the sampling frame for the present study. A 1:3 subsample was selected by including every third person registered in the voters list of 7,218 individuals (3,863 men, 3,355 women). A total of 2,406 individuals (1,266 men, 1,140 women) were invited to participate in the study. Fifty-nine of these individuals were unavailable to participate because they were migrant laborers, and another 172 did not give consent (overall population participation rate, ≈90%). An additional 219 individuals were excluded because of any amount of alcohol intake (n = 168) or other comorbidities (n = 51) that were deemed exclusionary in view of their possible influence on the study implementation and outcome (Fig. 1). Another 45 individuals who tested positive for chronic hepatitis viral infections (HBV and HCV) were also excluded. This yielded a final population sample of 1,911 individuals (Fig. 1).

Alcohol and drug intake were excluded and laboratory studies were performed (see Supporting Information for details).

Study Design. A multistage staggered approach starting in the community and then detailed analysis in the Institute was used (Fig. 1).

In the first phase, which was performed in the community, all subjects who consented to participate were interviewed by a trained public health nurse in the form a structured questionnaire to derive socio-economic and demographic data as well as details of drug intake and alcohol use. Subsequently, anthropometric measurements (height, weight, body mass index, and waist circumference) were performed (see Supporting Information). Obesity was defined by body mass index (BMI) according to World Health Organization standards,[18] and abdominal obesity (waist circumference >90 cm for men, >80 cm for women) was defined according to the International Diabetes Federation's cutoff for South Asians.[19] Components of MS were defined according to International Diabetes Federation criteria.

At the end of the interview, blood samples were collected for estimation of liver enzymes, fasting plasma glucose (FPG), and viral markers. Finally, hepatic ultrasonographic examination was performed by a single radiologist (D. B.) using a portable ultrasound

Address reprint requests to: Abhijit Chowdhury, Professor and Head, School of Digestive and Liver Diseases, Institute of Postgraduate Medical Education and Research, Kolkata 700020, India. E-mail: achowdhury2002@yahoo.co.in; Fax: (91)-3322235435.

Published online in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/hep.23567

Potential conflict of interest: Nothing to report.

Additional Supporting Information may be found in the online version of this article.



Fig. 1. Study algorithm. *Of the 219 subjects excluded, 168 had a history of alcohol intake, 28 had tuberculosis and were receiving directly observed therapy for tuberculosis, nine had obstructive airway disease, six were on antileprosy drugs, five had general geriatric debility, and three had advanced cardiovascular disease.

device (Sonosite 180 Plus®, SonoSite Inc., USA) after a 6-hour fast.

Subjects with fatty liver on ultrasonographic examination, diagnosed by standard criteria,[20] were designated as having probable NAFL (n = 189).

In the second phase, which was performed in an institutional setting, subjects with probable NAFL underwent nonenhanced computed tomography (CT) examination (Asteon, Toshiba, Japan) for confirmation of fatty liver, defined by a liver attenuation index of ≤ -14 HU on CT.[21]

Subjects with fatty liver on both imaging modalities used (ultrasonography and CT) were designated as having definite NAFL (n = 167).

To identify the role of MS and IR in NAFL, a nested case-control study was performed between subjects with definite NAFL versus age- and sex-matched controls drawn from the same background population. Three individuals did not agree to participate, leaving a final cohort of 164 individuals (cases). Besides the anthropometric data already recorded, skin-fold thicknesses at various sites were recorded using Lange calipers. Blood pressure was recorded in the left arm with the subject in a supine position after 5 minutes of rest using a mercury spyghmomanometer. Total body fat mass and percentage were assessed using leg-to-leg bioelectrical impedance analysis equipment (Tanita Corporation, Tokyo, Japan) in a fasting state by standard methodology.[22] Laboratory parameters analyzed included serum fasting lipid profile, C-reactive protein and iron levels, repeat FPG, alanine aminotransferase (ALT), and aspartate aminotransferase.

In the final phase, subjects with definite NAFL who had persistently elevated ALT levels (>40 U/L in both sexes at both the first and second phase of the study) were defined as having potentially significant NAFL. These subjects underwent transient elastographic examination (Fibroscan, Echosense, Paris) performed by a single operator (K. D.) for liver stiffness measure (LSM). An LSM value >8 kPa was considered abnormal, reflecting significant liver fibrosis.[23] Liver biopsy was performed using an 18-gauge Menghini needle as described[24] in subjects with potentially significant NAFL who consented. Liver tissue was stained with hematoxylin-eosin, reticulin, and Masson's trichrome stains. Histological assessment included determination of relevant objective parameters, NAFLD activity score, and NAFLD fibrosis score[25] by a single pathologist (A. R. M.) blinded to the clinical data.

Consent and Ethical Clearance. Informed consent was obtained from all participants prior to interviews and investigations at each phase. The study was approved by the Institutional Review Board of the Institute of Postgraduate Medical Education and Research, Kolkata, India.

Statistical Analysis. Means, medians, standard deviations (SDs), ranges, and proportions were calculated as appropriate. For parametric data, categorical variables were compared using Pearson's chi-square test or Fisher's exact test, and continuous variables were

Table 1. Characteristics of Study Population and NAFL Subjects

Parameters (Normal Range)	Total (n = 1,911)	Subjects With NAFL (n = 164)	Subjects Without NAFL (n = 1,747)
Age, years (mean ± SD)*	35.5 ± 12.4	39.0 ± 12.7	35.2 ± 12.3
Male sex (%)	53	54	53
Occupation (%)†			
Manual laborer	59	46	60
Other occupations	41	54	40
Economic status (%)*,‡			
<$1.00/day	48	31	50
$1.00-$2.00/day	42	48	41
>$2.00/day	10	21	9
Educational status (%)			
Up to primary level	61	51	62
Secondary level	19	23	19
Higher secondary level and above	20	26	19
Presence of smoking habit (%)	29	31	28
BMI, kg/m^2 (mean ± SD)*	19.6 ± 6.6	23.0 ± 4.2	19.3 ± 6.7
Persons having BMI (%)*			
<18.5	47	12	49
18.5-22.9	40	40	40
23.0-24.9	6	23	6
≥25.0	7	25	5
Presence of abdominal obesity§ (%)*	11	39	7
Fasting blood glucose, mg/dL (mean ± SD)*	80.0 ± 23.8	93.5 ± 38.1	78.7 ± 21.4
FBG >100 mg/dL (%)*	13	26	12
ALT, IU/L (mean ± SD)†	29.9 ± 26.2	35.3 ± 23.4	29.4 ± 26.4

*$P < 0.001$ between subjects with and without NAFLD.
†$P < 0.01$ between subjects with and without NAFLD.
‡Expressed in US dollars ($).
§Abdominal obesity was defined as waist circumference ≥90 cm in men and ≥80 cm in women.

compared using the Student *t* test or analysis of variance. For nonparametric data, we used Fisher's exact test for categorical data and the Mann-Whitney U or Kruksall-Wallis H test for continuous variables. Spearman's rho was calculated as appropriate. Binary logistic regression was performed using presence of NAFL, a qualitative dichotomous outcome, as a dependent variable to calculate the odds ratio and for multivariate analysis. The α level adopted for significance was $P < 0.05$ (two-tailed). Statistical analysis was performed using SPSS version 13 software (SPSS, Chicago, IL).

Results

Population Profile. The mean (±SD) age of the 1,911 subjects in the study was 35.5 ± 12.4 years (men, 35.9 ± 13.0 years; women, 35.1 ± 11.6 years), with a male:female ratio of 1.1:1. The majority were agricultural workers and/or manual laborers (59% [men, 70%; women, 50%]) and were economically poor (household income <$2.00/day in 90%). The mean (±SD) BMI was in the lower normal range (19.6 ± 6.6 kg/m^2 [men, 19.5 ± 8.2 kg/m^2, women, 19.7 ± 3.9 kg/m^2]). Only 7% (men, 6%; women, 8%) of the study population were overweight (BMI >25 kg/m^2). Eleven percent of the entire population had abdominal obesity. The majority of the individuals in the population were undernourished, with 47% having a BMI <18.5 kg/m^2. Twenty-nine percent were smokers and were predominantly men (36% versus women, 3%). The prevalence of dysglycemia (FPG >100 mg/dL) was 13% (men, 12.5%; women, 13%). Overall, the population was young, poor, physically active, and nonobese, typical of rural settings in developing countries. The charachteristics of the study population are given in Table 1.

Prevalence of NAFL, Potentially Significant NAFL, and Cirrhosis. Overall, 8.7% (167/1,911) of the study population had definite NAFL. Potentially significant NAFL (NAFL with elevated liver enzymes) was present in 44 (2.3%).

Transient elastographic examination (Fibroscan, Echosense, Paris) to measure LSM was performed in all 44 subjects with potentially significant NAFL. The median (range) LSM was 8.1 (3.7-46.4) kPa, and 26/44 (58%) subjects had significant liver fibrosis (LSM >8 kPa). The mean (±SD) interquartile range was 0.9 (±0.9) kPa, and the median success rate of acquisition was 100% (range, 60%-100%). LSM did not correlate with NAFLD activity score, age, and sex (data not shown), but showed a positive correlation with increasing stages of fibrosis (Spearman's rho, 0.55).

Table 2. Characteristics of 36 Patients Who Underwent Liver Biopsy

Parameters	Values
Median age, years (range)	40 (22-70)
Sex (male:female), n	23:13
Median BMI, kg/m^2 (range)	25.6 (18.7-37.3)
Median LSM, kPa (range)	8.1 (2.6-46.4)
Median length of liver tissue, cm (range)	2.0 (1.5-3.5)
Steatosis grade, n:	
Grade 1	19
Grade 2	10
Grade 3	7
NAFLD fibrosis stage, n:	
Fibrosis stage 0	17
Fibrosis stage 1A	9
Fibrosis stage 2	6
Fibrosis stage 4 (cirrhosis)	4
NASH (NAFLD activity score $\geq$5), n (%)	11 (31)
Median NAFLD activity score (range)	4 (0-7)

Of the 44 subjects with potentially significant NAFL, 36 (82%) agreed to undergo liver biopsy (Table 2). Steatosis was seen in all subjects. Histologic nonalcoholic steatohepatitis (NASH) (NAFLD activity score of $\geq$5) was seen in 11/36 (31%) subjects, four of whom had cirrhosis. Thus, 2.4% (4/167) of subjects with NAFL had cirrhosis. The prevalence of cirrhosis in the entire population was at least 4/1,911 (0.2%).

Mean ($\pm$SD) LSM values were significantly higher in subjects with stage 2 and stage 4 fibrosis/cirrhosis than those with stage 1A fibrosis (Fig. 2). The four patients with cirrhosis were recalled for re-evaluation after liver biopsy and had a negative autoimmune and Wilson's work-up.

Subjects with NAFL. The prevalence of NAFL was similar in both males (88/1018 [8.6%]) and females (76/893 [8.5%]). Subjects with NAFL were older than those without NAFL. The prevalence of fatty liver increased with age in both sexes with the peak prevalence attained by the fourth decade in men and women (data not shown).

Although the average income of the population was low, subjects with NAFL were more likely to be economically better off than those who did not have fatty liver (income >$2.00/day; 21% versus 9%, respectively [$P < 0.001$]). There was no significant difference in the educational status of the two groups. Persons with NAFL were, however, less likely to be as physically active as manual laborers (46% versus 60% [$P < 0.01$]). They had a higher BMI, a higher prevalence of abdominal obesity, a higher mean fasting plasma glucose, and a higher prevalence of dysglycemia (FPG >100 mg/dL). Their mean ALT levels were also higher (Table 1).

In multivariate analysis (Table 3), after adjusting for age and sex, the odds ratio (OR) of having NAFL independently rose with increasing income (income $1.00-$2.00/day, OR 1.8 [$P = 0.05$]; income >$2.00/day, OR 2.4 [$P = 0.01$]) and with the presence of dysglycemia (OR 2.6 [$P = 0.001$]) and abdominal obesity (OR 3.6 [$P < 0.001$]). Having a normal BMI (18.5-24.9 kg/m^2) was associated with a 2-fold increased risk of having fatty liver (OR 2.0 [$P = 0.03$]). The highest risk was in those with a BMI > 25 kg/m^2 (OR 4.3 [$P = 0.001$]).

However, despite having a higher mean BMI, most of the NAFL subjects (75%) were not overweight; 103/164 (63%) had normal BMI (18.5-24.9 kg/m^2), and 20/164 (12%) were underweight (BMI <18.5 kg/m^2). Abdominal obesity was present in only 39% of NAFL subjects. Ninety subjects (54%) with NAFL



Fig. 2. Distribution of LSM in different stages of fibrosis. Mean ($\pm$SD) LSM values were: stage 0/no fibrosis, 8.4 $\pm$ 2.3 kPa; stage 1A, 7.2 $\pm$ 2.4 kPa; stage 2, 11.7 $\pm$ 5.2 kPa; stage 4/cirrhosis, 24.9 $\pm$ 13 kPa.

Table 3. Multiple Logistic Regression for Risk Factors for NAFL in the Whole Population

Variables	OR (95% CI)	*P* Value
Presence of abdominal obesity*	3.6 (1.7-7.2)	<0.001
Presence of dysglycemia (FBG >100 mg/dL)	2.6 (1.5-4.6)	0.001
Family income†		
<$1.00/day	1.0	
$1.00-$2.00/day	1.8 (1.0-3.2)	0.05
>$2.00/day	2.4 (1.2-5.0)	0.01
BMI		
<18.5 kg/m^2	1.0	
18.5-24.9 kg/m^2	2.0 (1.1-3.8)	0.03
$\geq$25 kg/m^2	4.3 (1.6-11.5)	0.001

Age, sex, and profession did not achieve statistical significance.

*Abdominal obesity was defined as a waist circumference $\geq$90 cm in men and $\geq$80 cm in women.

†Expressed in US dollars ($).

Table 4. Comparison of Subjects With and Without NAFL (Nested Case-Control)

Parameters	Cases with NAFL (n = 164)	Controls Without NAFL (n = 164)	*P* Value
Age, years (mean ± SD)	39 ± 13	39 ± 13	NS
Sex (male:female), n	88:76	88:76	NS
Anthropometric values			
BMI, kg/m^2 (mean ± SD)	22.70 ± 3.90	20.60 ± 5.10	NS
BMI categories, n (%)			
<18.5 kg/m^2	20 (12)	55 (33)	
18.5-24.9 kg/m^2	103 (63)	107 (65)	
≥25 kg/m^2	41 (25)	2 (1)	
Waist circumference, cm (mean ± SD)	80.01 ± 12.10	75.00 ± 9.01	0.03
Presence of abdominal obesity (%)	39	18	<0.0001
Triceps skin-fold thickness, mm (mean ± SD)	10.00 ± 5.70	9.00 ± 5.20	0.05
Subscapular skin-fold thickness, mm (mean ± SD)	17.02 ± 8.30	14.40 ± 7.30	0.05
Fat percentage (mean ± SD)	20.9 ± 6.9	14 ± 7.4	0.001
FBG, mg/dL (mean ± SD)	94 ± 37	80 ± 21	NS
FBG >100 mg/dL, n (%)	43 (26)	21 (13)	<0.001
Serum insulin, mIU/mL (mean ± SD)	7.90 ± 4.81	6.7 ± 2.28	NS
HOMA-IR (mean ± SD)	2.24 ± 3.16	1.44 ± 0.96	0.02
Presence of diabetes,* n (%)	12 (7)	7 (4)	<0.001
Triglyceride, mg/dL (mean ± SD)	125.9 ± 65	98 ± 36	0.05
HDL, mg/dL (mean ± SD)	44 ± 12.3	41.6 ± 7.4	0.04
Total cholesterol, mg/dL (mean ± SD)	179.3 ± 63.6	177 ± 48	0.001
Hypertension, n (%)	10 (6)	7 (4)	<0.001
ALT >40 IU/L, n (%)	44 (27)	25 (15)	<0.01
CRP, mg/dL (mean ± SD)	2.3 ± 1.3	2.0 ± 1.0	NS

*The presence of diabetes was based on FBG only, which may underestimate the fact.

Abbreviations: CRP, C-reactive protein; HDL, high-density lipoprotein; NS, not significant.

were neither overweight nor had abdominal obesity. NAFL subjects with BMI <18.5 kg/m^2 were significantly younger and had significantly lower mean total serum cholesterol, body fat content (as fat percentage assessed by leg-to-leg bioelectrical impedance), and prevalence of abdominal obesity than NAFL subjects who had normal BMI or who were overweight (Supporting Table 1).

Nested Case-Control Analysis. In this subanalysis of 164 cases with NAFL and 164 controls without NAFL (Table 4), NAFL subjects were significantly more likely to be overweight (BMI >25 kg/m^2, 25% versus 1%; [$P < 0.0001$]), have abdominal obesity, and a significantly higher body fat content (mean ± SD fat percentage, 20.9 ± 6.9% versus 14 ± 7.4% [$P < 0.001$]). They had higher triceps and subscapular skin-fold thicknesses, although the difference achieved borderline significance. Subjects with NAFL were more likely to have dysglycemia and had a higher mean value for homeostatic model assessment of insulin resistance (HOMA-IR). Although they were more likely to be hyperinsulinemic, the difference did not achieve statistical significance. They also had significantly higher mean serum levels of total cholesterol, high-density lipoprotein cholesterol, and triglycerides and had a higher frequency of hypertension. Thus, subjects with NAFL were more likely to have abnormalities in various components of MS than those without NAFL.

On multivariate analysis (data not shown), using BMI, abdominal obesity, HOMA-IR (marker for dysglycemia), and high-density lipoprotein levels (marker for dyslipidemia), having a BMI in the normal range (18.5-24.9 kg/m^2 [OR 2.5, 95% confidence interval (CI) 1.4-4.6 ($P < 0.01$)] or >25 kg/m^2 [OR 53, 95% CI 11.5-240 ($P < 0.001$)]) and a rising HOMA-IR (OR 1.2, 95% CI 1.0-1.4 [$P = 0.05$]) were independently associated with an increased risk of NAFL.

Nonobese NAFL. As both the NAFL subjects and general population had a low prevalence of overweight or abdominal obesity, we conducted a subgroup comparative analysis among the cases and controls who had BMI <25 kg/m^2 as well as a normal waist circumference (Table 5). Even within this subgroup, the mean values for BMI; skin-fold thicknesses from various sites; body fat percentage; and serum FPG, triglyceride, and total cholesterol levels were significantly elevated in the NAFL subjects. On multivariate analysis, even in this subgroup with no obesity, the only two independent predictors of fatty liver were increased BMI (OR 1.2, 95% CI 1.1-1.4 [$P < 0.01$]) and biceps skin-fold thickness (OR 1.2, 95% CI 1.1-1.3 [$P < 0.01$]).

In order to clarify the role of MS in the subgroup of NAFL subjects with BMI <18.5 kg/m^2, a comparative case-control analysis was performed (Supporting Table 2). Compared with controls with BMI <18.5

Table 5. Comparison of Nonobese NAFL Cases With Nonobese Controls

Parameters	Nonobese NAFL Cases (n = 90)	Nonobese Controls (n = 134)	*P* Value
Age, years (mean ± SD)	36 ± 13	39 ± 13	NS
Sex (male:female), n	63:27	81:53	NS
Anthropometric values			
BMI, kg/m^2 (mean ± SD)	20.7 ± 2.7	19.5 ± 2.7	0.002
Waist circumference, cm (mean ± SD)	73.01 ± 9.12	72.23 ± 8.32	NS
Biceps skin-fold thickness, mm (mean ± SD)	7.0 ± 4.0	4.9 ± 2.2	<0.0001
Triceps skin-fold thickness, mm (mean ± SD)	10.6 ± 6.0	8.0 ± 4.2	0.002
Subscapular skin-fold thickness, mm (mean ± SD)	17.6 ± 7.8	13.1 ± 6.7	<0.0001
Suprailiac skin-fold thickness, mm (mean ± SD)	13.7 ± 8.4	8.3 ± 4.6	<0.0001
Fat percentage (mean ± SD)	18.5 ± 5.9	12.3± 6.0	<0.0001
FPG, mg/dL (mean ± SD)	86 ± 25	80 ± 20	0.03
Serum insulin, mIU/mL (mean ± SD)	6.83 ± 3.24	6.66 ± 2.19	NS
HOMA-IR (mean ± SD)	1.63 ± 1.65	1.41 ± 0.89	NS
Triglyceride, mg/dL (mean ± SD)	118.2 ± 66.3	93.4 ± 34.6	0.001
HDL, mg/dL (mean ± SD)	43.6 ± 12.7	41.8 ± 7.3	NS
Total cholesterol, mg/dL (mean ± SD)	159.4 ± 60.4	177.7 ± 50.3	0.02
ALT >40 IU/L n (%)	21 (23%)	21 (15.8%)	NS
CRP, mg/dL (mean ± SD)	1.9 ± 1.0	2.0 ± 0.9	NS
Ferritin, mg/dL (mean ± SD)	39 ± 14	38 ± 15	NS

A nonobese person was defined as having a BMI <25 kg/m^2 and a waist circumference <90 cm in men and <80 cm in women.
Abbreviations: CRP, C-reactive protein; HDL, high-density lipoprotein; NS, not significant.

kg/m^2, NAFL subjects had significantly higher skin-fold thicknesses, body fat percentage, and mean serum triglyceride levels but lower mean serum total cholesterol levels. They also had a higher prevalence of hypertension and higher mean serum FPG, although there was no statistically significant difference in the markers of dysglycemia.

Discussion

In this prospective multistaged community-based epidemiological study performed in a rural Indian population, we found an 8.7% prevalence of NAFL, including ≈0.2% prevalence of cryptogenic cirrhosis. The major methodological strengths of our study are its population-based prospective design, adoption of stringent imaging criteria for diagnosis of fatty liver, strict exclusion of alcohol consumption and viral hepatitis to derive a true metabolic fatty liver and, most importantly, performance of liver biopsy in a significant subset of NAFL subjects for the first time in an epidemiological study of NAFL.

We found a high prevalence of NAFL (8.7%), potentially significant NAFL (2.3%), and silent cirrhosis (≈0.2%). This is intriguing considering that 47% of our study population had a BMI <18.5 kg/m^2 and 87% had normal BMI. Remarkably, three fourths of those with NAFL were not even overweight, and half of them had neither generalized nor abdominal obesity. This was a reflection of the very low (7%) overall prevalence of overweight individuals in the population. Despite this, the association of NAFL with MS and adiposity was preserved, albeit in a modified manner. The linear association of increasing obesity with increasing prevalence of NAFL in the population, is established in developed countries as well as the socio-economically upward moving segment of the low to middle income nations,[10-12,14,15] although the vast majority of the world population live beyond the boundaries of such social order. The present study is unique in that it expands the NAFL ambit beyond its classical overweight-obesity paradigm. It also provides evidence, for the first time, that fatty liver will be an important determinant of liver disease burden even in the poor and emerging economies, where a disease burden transition is already occurring.[2,26]

Previous epidemiological studies have mostly been in a preselected population[12,14] or did not completely exclude alcohol consumption[11,12,14,15] or viral hepatitis[15] in calculating prevalence data of NAFL. Two previous well-designed community studies on NAFL are the Dionosys study from Italy[14] and the Minnesota study from the United States.[27] Whereas the former study was an epidemiological one, the latter was a clinically defined cohort providing useful information on the epidemiology of NAFL in developed countries as well as liver disease behavior. However, the NAFL prevalence reported here is lower than other imaging-based epidemiological studies (15%-29%).[9,28] The stepwise dual-screening using both ultrasonography and CT, rigid exclusion of alcohol intake, younger age, and low background prevalence of obesity and MS

may explain the lower prevalence figures reported here. What is more concerning is the fact that, as the population ages, the prevalence of fatty liver will rise with its consequent health burden.

Another remarkable feature of this study is the provision of histological evaluation of the liver in a community sample of NAFL subjects. Absence of histology has been a persistent lacunae of epidemiological studies of NAFL.[9,28] Elevated ALT in NAFL is indicative of the presence of NASH and fibrosis.[28] Therefore, using this as our guide, we selected a subset of potentially significant NAFL for biopsy, because our Institutional Review Board allowed us to perform liver biopsy, with its attendant potential complications,[29] in only those NAFL subjects who had abnormal liver enzymes. Histologically, NASH and silent cirrhosis was found in 31% and 2.4%, respectively, of those subjects with NAFL and elevated ALT who consented to liver biopsy. This is lower than the 76% and 2% baseline prevalence of NASH and cirrhosis, respectively, in a community-based cohort study from Minnesota.[27] This can be attributed to the higher prevalence of obesity in the Minnesota cohort compared with our population (71% versus 25%, respectively). Moreover, the Minnesota cohort was made up of subjects who had visited the physician and had a diagnosis of fatty liver and therefore was clinically assembled with a referral bias. Our NAFL subjects were detected on population screening, hence our data are more representative of the general population as seen in our country. It should be stressed that NAFL subjects with normal ALT may also harbor advanced liver disease,[28] indicating that our figures may have underestimated the true prevalence of NASH or cirrhosis. On the other hand, we found histological NASH in only one third of our patients with NAFL and elevated enzymes underscoring the fact that elevated ALT may be a poor surrogate marker of underlying NASH in subjects with fatty liver.

IR has been implicated in the pathogenesis of NAFL.[8,9,28] The fact that elevated BMI, abdominal obesity, and dysglycemia (represented by either a FPG $>$100 mg/dL or increasing HOMA-IR), all markers of IR, were independent risk factors of NAFL, even within this predominantly nonobese population, upholds the strong biological relationship of NAFL with MS or IR across socio-economic and anthropometric phenotypes. According to the thrifty-genotype hypothesis,[30] IR has evolved as an energy-conserving mechanism in humans in the face of historical relative lack of abundance of food in pre-agricultural society. This has become maladaptive in situations of energy excess and sedentarism, usually associated with economic prosperity. In our population comprised predominantly of manual laborers, NAFL subjects were more likely to have a higher income and less likely to be manual laborers than subjects without NAFL. Moreover, on multivariate analysis, increasing family income and even a normal BMI were independent risk factors for NAFL. These suggest the subtle unfolding of maladaptive potential of IR in the form of NAFL in our population.

Asians have increased body fat compared with Europeans, even at the same BMI.[19] This may also explain why a normal BMI was an independent risk factor for NAFL in our study. This is partly supported by the fact that, in the case-control analysis, the body fat content, measured as body fat percentage by bioelectric impedance analysis, was significantly higher in subjects with NAFL. The increased risk of NAFL with abdominal obesity, the higher subcutaneous skin-fold thicknesses in the NAFL subjects, and the increased risk of NAFL with increasing biceps skin-fold thickness in the subgroup of nonobese NAFL are important highlights of our study. Moreover, the fact that even NAFL subjects with BMI $<$18.5 kg/m^2, compared with controls with BMI $<$18.5 kg/m^2, had increased markers of adiposity in the form of higher subcutaneous skin-fold thicknesses and higher body fat percentage on bioelectric impedance analysis should provoke the need for more studies on the complex relationship of body fat patterning with liver fat deposition in different ethnic groups. The recent discovery of an ethnicity-specific association between the genes encoding a fat-metabolizing protein with NAFL further augments the relationship between genes, ethnicity-specific body-fat distribution, and NAFL.[31]

Another noteworthy feature is that 12% of NAFL subjects had undernutrition (BMI $<$18.5 kg/m^2). Could undernutrition also be responsible for NAFL in our population? Studies in humans have demonstrated that liver accumulates fat during starvation in adults[32] or during protein-energy malnutrition in children.[33] Molecular pathogenesis of obesity-associated liver disease and undernutrition-related liver damage are quite similar.[34,35] To answer this question, we conducted a case-control study of subjects with and without NAFL with a BMI $<$18.5 kg/m^2 and looked for markers of adiposity and MS. Interestingly, even in this subgroup, subjects with NAFL had higher indices of adiposity and higher prevalence of markers of MS versus those without NAFL. This highlights for the first time a "*third-world NAFL*" phenotype in which, instead of overt obesity, subtle measures of increased adiposity predispose to NAFL.

Transient elastography, though not well validated for measuring fibrosis in NAFLD, has been used in liver disease of different etiologies.[36-38] Despite being used in NAFLD, the issue of whether steatosis and inflammation influence the stiffness value is not yet settled.[27] However, studies that included liver diseases of various etiologies report nonuniformity of cutoff values for exclusion of cirrhosis among different etiologies. Higher cutoff value for LSM was reported to achieve best diagnostic accuracy and acceptable sensitivity and specificity for NAFLD.[36] LSM values increase with increasing stages of fibrosis in NAFLD.[37] Significant correlation was also demonstrated between LSM and stages of fibrosis,[38] which was also reproduced in our study.

One weakness of our study was our inability to do the full component of all MS parameters in all subjects and the fact that our population sample is not representative of all the diverse socio-demographic groups in our country. Thus, previous studies in urban Indians involving smaller sample sizes and having higher baseline obesity have reported a higher prevalence of fatty liver on ultrasound.[39,40] While acknowledging these limitations, the data presented herein mandate the need for larger study sample and inclusion of a wider battery of metabolic parameters at baseline.

In conclusion, our study found a significant prevalence of NAFL and cryptogenic cirrhosis in a predominantly poor, nonobese, nonsedentary population. Abdominal obesity, overweight, dysglycemia, rising income, and even a normal BMI were found to be independent risk factors of NAFL in our population.

Acknowledgment: We thank the field staff of the Liver Foundation, as well as the laboratory staff (Sumanta Sarkar, Pratap Pandit) and research fellows Ayan Biswas and Subhadip Ghatak of the School of Digestive and Liver Diseases, Institute of Postgraduate Medical Education and Research, for their cooperation. We also thank Mediclue Diagnostic & Research Centre, Kolkata, for helping with serum insulin, iron, ferritin, and C-reactive protein estimations.

References

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-1276.
2. Williams R. Global challenges in liver disease. HEPATOLOGY 2006;44: 521-526.
3. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-1133.
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al., for the REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
5. Kim WR, Brown Jr RS, Terrault N, El-Serag H. Burden of liver disease in the United States: summary of a workshop. HEPATOLOGY 2002:36; 227-242.
6. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-1757.
7. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007;370:1929-1938.
8. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
9. Wilfred de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48:S104-S112.
10. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL, for the Asia-Pacific Working Party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007;22:788-793.
11. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508-514.
12. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-728.
13. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world—a growing challenge. New Eng J Med 2007;356:213-215.
14. Bedogni G, Miglioli L, Masutti F, Tiribelli C. Prevalence and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. HEPATOLOGY 2005;42:44-52.
15. Browning JS, Szczepaniak LS, Dobbins LS, Nuremberg R, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004;40:1387-1395.
16. Chowdhury A, Santra A, Chaudhuri S, Dhali GK, Chaudhuri S, Maity SG, et al. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. HEPATOLOGY 2003;37: 802-809.
17. Chowdhury A, Santra A, Chakravorty R, Banerji A, Pal S, Dhali GK, et al. Community-based epidemiology of hepatitis B virus infection in West Bengal, India: Prevalence of hepatitis B e antigen-negative infection and associated viral variants. J Gastroenterol Hepatol 2005;20: 1712-1720.
18. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implication for policy and intervention strategies. Lancet 2004;363:157-163.
19. Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet 2005;366:1059-1062.
20. Quinn SF, Gosink BB. Characteristic sonographic signs of hepatic fatty infiltration. AJR Am J Roentgenol 1985;145:753-755.
21. Lee SW, Park SH, Kim KW, Choi EK, Shin YM, Kim PN, et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology 2007;244:479-485.
22. Tsui EYL, Gao XJ, Zinman B. Bioelectrical impedance analysis (BIA) using bipolar foot electrodes in the assessment of body composition in type 2 diabetes mellitus. Diabetic Med 1998;15:125-128.
23. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato F, Ranchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-973.
24. Menghini G. One-second needle biopsy of the liver. Gastroenterol 1958;35:190-199.
25. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005;41:1313-1321.
26. Ghaffar A, Srinath Reddy K, Singhi M. Burden of non-communicable diseases in South Asia. BMJ 2004;328:807-810.

27. Adams LA, Lymp JF, St. Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterol 2005;119:113-121.
28. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatits. Gastroenterol 2008;134:1682-1698.
29. Bravo AA, Sheth SG, Chopra S. Liver biopsy. New Eng J Med 2001; 344:495-500.
30. Neel JV. Diabetes mellitus: A "Thrifty" genotype rendered detrimental by "Progress"? Am J Hum Genet 1962;14:353-362.
31. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in *PNPLA3* confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1460-1465.
32. Moller L, Stodkilde-Jorgensen H, Jensen FT, Jorgensen JOL. Fasting in healthy subjects is associated with intrahepatic accumulation of lipids as assessed by ^{1}H-magnetic resonance spectroscopy. Clin Science 2008; 114:547-552.
33. Waterlow JC. Amount and rate of disappearance of liver fat in malnourished children in Jamaica. Am J Clin Nutr 1975;28:1330-1336.
34. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
35. Doherty JF, Golden MHN, Brooks SEH. Peroxisomes and the fatty liver of malnutrition: a hypothesis. Am J Clin Nutr 1991;54:674-677.
36. Ganne-Carrie N, Ziol M, Ledinghen VD, Douvin C, Marcellin P, Castera L, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. HEPATOLOGY 2006; 44:1511-1517.
37. Yoneda M, Fujita K, Inamori M, Nakajima M, Tamano M, Hiraishi H. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007;56:1330-1331.
38. Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008;40:371-378.
39. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007;6:161-163.
40. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009;84:84-91.

Hepatol Int (2013) 7 (Suppl 2):S806–S813
DOI 10.1007/s12072-013-9477-5

REVIEW ARTICLE

Lean NASH: distinctiveness and clinical implication

Kausik Das · Abhijit Chowdhury

Received: 27 May 2013 / Accepted: 16 September 2013 / Published online: 17 October 2013

Abstract
Introduction Non-alcoholic fatty liver (NAFL) in the absence of overweight and/or obesity, defined by the anthropometric parameter, body mass index (BMI), has been designated as 'lean NASH.' While maintaining a close pathophysiological link with metabolic syndrome (MS) and insulin resistance (IR), the presence of subtle alterations in measures of total body and regional adiposity not exceeding the designed cut-offs, are hallmarks of 'lean NASH.'
Material and methods Available literature related to non-alcoholic steatohepatitis (NASH) in lean or non-obese individuals and its pathogenesis in general published in English language journals till the time of manuscript preparation were reviewed and critically analysed.
Analysis Being a closely related but variant phenotype of NASH, its features metabolically resemble the well-characterized entity 'metabolically obese normal weight (MONW)' individuals. Apart from total body adiposity, distribution of fat in different body compartments has assumed greater pathophysiologic relevance in characterizing 'lean NASH'. Detection of NASH in stringently defined non-obese individuals, by both BMI and waist circumference indices, indicates existence of a subset of NASH in which fat compartmentalization at ectopic sites is not picked up by the anthropometric yardsticks used. Volume [Quantity] and biological behavior of the visceral and deep subcutaneous adipose tissues contribute to this variant of NASH in non-obese subjects. Genetic predisposition to IR and MS along with the environmental influences like childhood nutritional status, dietary composition and gut microbiome possibly play pathogenetic role.
Conclusion The most important concern is in the principles of nomenclature within syndromes where clinical dissimilarities exist despite biological similarities. Till a uniformly acceptable pathophysiological and/or etiology-based classification emerges, the term "lean NASH" would continue to provide us an opportunity to ponder over and refine this subset of fatty liver in non-obese people and potentially significant liver disease.

Keywords Obesity · Steatohepatitis · Adiposity · BMI · Waist circumference · Lean

Background

Non-alcoholic fatty liver (NAFL) and steatohepatitis (NASH) in the absence of overweight and obesity, defined by the anthropometric parameter body mass index (BMI), has been designated 'lean NASH.' The classical phenotype of NAFL is almost always associated with varying degrees of obesity [1]. Lean NASH is an exception in terms of its relationship with BMI, even though most of the pathophysiological changes that characterize metabolic syndrome (MS) and insulin resistance (IR) are present. Subtle alterations in measures of total body and regional adiposity not exceeding the designated cutoff values are features that indicate it is closely related to but a variation of classical NASH [2, 3]. Lean NASH was initially described in Asians. However, it has subsequently been reported from other countries, including in the West [4–7]. Remarkably, there is a shift in disease burden patterns in developing countries.

K. Das · A. Chowdhury (✉)
Department of Hepatology, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, 244 A.J.C. Bose Road, Kolkata 700020, India
e-mail: achowdhury2002@yahoo.co.in

K. Das
e-mail: kausikdasmail@gmail.com

There has been a greater prevalence of MS-associated chronic diseases in these countries—a scenario that the developed countries have long been experiencing [8]. This has led to a change in health care priorities in developing countries. MS-associated diseases in low- and middle-income countries often present with different phenotypes and also different clinical outcomes. It is under these circumstances that 'lean NASH' has grown from a regional curiosity to a distinct variant of NASH with biological plausibility. Many issues concerning the pathogenesis and natural history of NASH are still unclear. In complex diseases like NASH, alternate phenotypes are often of significant interest, as the underlying similarities in the presence of heterogeneity can provide biological clues that are often more difficult to tease out in the parent phenotype.

Evidence that LEAN NASH is a distinct phenotype

A subset of individuals, despite being obese, has preserved insulin sensitivity and does not develop adverse clinical outcomes. They are designated as 'metabolically healthy obese.' This contrasts with another group of individuals who are insulin resistant and have hyperinsulinemia, atherogenic lipid profiles, as well as hypertension, despite having normal BMIs, i.e., <25 kg/m^2 [9]. The latter are designated as metabolically obese normal weight (MONW), which is possibly closely related to lean NASH [9]. Asians, in general, have been shown to have a propensity to develop adverse metabolic clinical events at a comparatively lower BMI, and this has led to the recognition of racial and ethnic differences in body composition and fat distribution as determinants of metabolic health [10, 11].

Evidence of a non-obese phenotype of NAFLD was first reported from Asian countries (Table 1) [4, 5]. There was no difference in the pattern of metabolic abnormalities observed among those with normal weight, overweight, and obesity. Even in those with normal weight (non-obese group), the presence of central obesity and expanded visceral fat was associated with NAFL [5].

The 'lean NASH' paradigm received its conceptual fillip in a cross-sectional multiethnic study involving young, anthropometrically lean, nonsmoking, sedentary volunteers [11]. Asian Indian male were shown to have a lower mean insulin sensitivity index and higher mean homeostasis model assessment-insulin resistance (HOMA-IR) values along with correspondingly higher hepatic triglyceride (TG) content in comparison to their Caucasian, Black, and Hispanic counterparts. In addition, adipocytokine profiles were different in Asian Indian male, particularly IL-6 levels, indicating a state of a relatively higher degree of inflammatory activation. Besides, larger size of the adipocytes is demonstrated in South Asian male in comparison to Caucasians along with higher levels of non-esterified fatty acid and leptin and lower levels of adiponectin [10]. All this evidence suggests that MONW and lean NASH might represent the non-obese counterpart of the 'sick fat cell syndrome' of obesity and IR.

A more robust description of lean NASH, as a distinct phenotype, came from a community-based epidemiological study in West Bengal, India. The study revealed the prevalence of NAFL to be 8.7 % [12]. The study population was rural, physically active, and predominantly poor, with an average BMI of 19.6 ± 6.6 kg/m^2. Overweight and central obesity were present in 7 and 11 %, respectively. Histological changes in biopsied individuals showed that one third (31 %) of the subjects with NAFLD and elevated ALT levels had significant inflammatory activity (NAFLD activity score ≥ 5) that qualified as NASH, and 2.4 % had cirrhosis. Those who were non-obese/lean (BMI < 25 kg/m^2 with WC <90 cm in male and <80 cm in female) with NAFL had higher BMIs and levels of subcutaneous fat, fasting blood glucose (FBG), and TG in comparison to the non-obese control group. While these biological similarities with the classical phenotype strengthen the notion that both are part of the same disease, 'lean NASH' qualifies as an alternate phenotype with a distinct relationship with adiposity, albeit with some differences. Recently, genome-wide association studies (GWAS) have identified several loci that influence adiposity and fat distribution [13]. Thus, a convergence of clinical, epidemiological and genetic data would suggest that the ethnic differences in body fat distribution and relative adiposity are critical in determining the obesity phenotypes as well as their relationship with defined clinical syndromes like NASH (Fig. 1).

Pathogenesis

Adiposity, BMI and lean NASH

Availability of excess calories due to socioeconomic affluence and sedentary lifestyles leads to obesity, with the excess energy being stored as fat. Accumulation of fat in the liver, the cardinal feature of NAFL, also occurs in this setting and is an expression of an expanded adipose tissue mass in the body. The prevalence of NAFL in a population has a good correlation with measures of obesity. In addition, progression from NAFL to NASH is also higher with increasing degrees of obesity—indicating the intimate relationship between overall fat mass and NASH prevalence and outcomes [1].

In general, adipose tissue is not only expanded in MS-related conditions, but is also more likely to be dysfunctional, triggering inflammatory responses that set into motion the diffuse functional changes that occur in MS and in NASH as part of its hepatic manifestation [14]. The large mass of fat tissue in the body, despite its diffuse nature and existence in multiple localizing compartments, is now regarded as an organ by itself. Adipose tissues in

Table 1 Summary of the studies reporting metabolic abnormalities in lean/non-obese subjects

References	Country	Population (*n*)	Subject with BMI <25 kg/m^2 (*n*)	Non-obese Subjects with NAFLD	Definition of leanness/non-obese used	Prevalence of abdominal obesity in lean NAFLD	Prevalence of metabolic abnormalities in lean NAFLD	Risk factors for NAFLD in non-obese subjects	Ref no.
Chen et al. [4]	Taiwan	General population ($n = 3,245$)	1,444	61 (4.2 %)	BMI < 25 kg/m^2	NR	FPG ≥126 mg/dl in 9 TG ≥150 mg/dl in 34	Age 40–64 years, elevated ALT and TG ≥150 mg/dl	7
Das et al. [12]	India	General population ($n = 1,911$)	1,777	90	BMI < 25 kg/m^2 WC <90 cm (male) and <80 cm (female)	–	Mean ± SD FBG 86 ± 25 mg/dl Mean ± SD TG 118.2 ± 66.3 mg/dl	Higher BMI (OR 1.2; 95 % CI 1.1–1.4; $p < 0.01$), higher biceps skinfold thickness (OR 1.2; 95 % CI 1.1–1.3; $p < 0.01$)	24
Kim et al. [2]	Iceland	General population ($n = 2,495$)	941	NR	BMI < 25 kg/m^2	NR	NR	Significant association between VAT and MS in lower BMI (<25 and 25–29.9 kg/m^2)	6
Margariti et al. [7]	Greece	NAFLD patients attending Liver clinic ($n = 162$)	19	–	BMI < 25 kg/m^2	33 %	MS 20 % diabetes 5 %	–	10
Younossi et al. [6]	US	National Health and Nutrition Examination Survey (NHANES III) ($n = 11,613$)	4,475	431 (7.39 %)	BMI < 25 kg/m^2	8.05 %	Diabetes 6.72 % hypercholesterolemia 62.65 %	Younger age, female gender	9
Kim et al. [5]	Korea	Clinic based medical check-up ($n = 786$)	460	74 (16 %)	BMI < 25 kg/m^2	35 %	Hypertriglyceridemia 60.8 % IFG 8.1 %	Male gender, higher WC, TG and IR	8

BMI body mass index, *WC* waist circumference, *NAFLD* non-alcoholic fatty liver disease, *FPG* fasting plasma glucose, *FBG* fasting blood glucose, IFG impaired fasting glucose, *TG* triglyceride, *MS* metabolic syndrome, *IR* insulin resistance, *VAT* visceral adipose tissue, *OR* odds ratio, *CI* confidence interval, *SD* standard deviation, *NR* not reported



Fig. 1 Comparative pathophysiological hypothesis of 'lean NASH'

different locations maintain a functionally harmonious relationship and cross-talk with each other, responding to different perturbations of the metabolic–inflammatory milieu in the body, and therefore, they become relevant in health and disease [14]. In light of this, measures of adiposity have all along been a key element in the definition of MS and also relevant to evaluation of NASH.

BMI is the most simple and commonly used measure of total body adiposity in clinical as well as epidemiological studies. It has shown a linear relationship with overall mortality in a population, primarily by virtue of its association with MS [15]. Lean NASH shares the metabolic features and hepatic pathology in the absence of linearity of association with adiposity, as seen in classical NASH [16].

Compartmentalization of adipose tissue: the context of 'lean NASH'

BMI is regarded as a surrogate of body fat content. There is complex interaction among different body compartments such as adipose tissue, skeletal muscle, and osseous elements. Adipose tissue is the most dynamic of all these components [17]. However, it has been observed that the sensitivity of a specific BMI cutoff value to identify the correlation between the degree of fatness and increased risk of health hazards varies across different populations as well as among individuals with different energy reserves [18]. Asian Indians, in particular, show a higher prevalence of abdominal obesity reflected in higher waist:hip ratios (WHRs) and higher truncal subcutaneous fat, especially deep subcutaneous adipose tissue, even when they have 'normal' BMIs [3, 19] (Fig. 2). These features, along with shorter height and lower lean body mass, lead to a higher propensity to develop IR and MS at a lower BMI [3]. In addition, comparable to obese subjects, non-obese subjects who gain weight despite being within the range of normal BMI or currently normal weight individuals who were obese in the past are found to have increased risk of NAFL and type 2 diabetes [20, 21]. This emphasizes the need to consider BMI within a dynamic frame rather than as a single-point observation. Another limitation of BMI is that it falls short of capturing the subtle changes in amount and disposition/distribution of fat tissue that occur in lean NASH, thus making it a suboptimal marker of adiposity in this setting. Despite all these considerations, a WHO expert committee rejected a proposition to revise the current BMI cutoff values for metabolic health risks as a general principle, but acknowledges the heterogeneity in the strength of racial, ethnic, and individual differences in BMI in such settings [18]. Family and twin studies have shown that BMI, as a marker of obesity, has a 40–70 % component of heritability [13]. Subsequent GWASs have identified several loci, particularly fat mass and obesity associated (FTO) gene and MC4R, as potential genetic determinants of BMI [13]. Although the strength of such associations has generally been modest, they emphasize the complex nature of the interaction between genetic and environmental factors in determining the degree and pattern of adiposity.

Apart from total body adiposity, the distribution of fat in different body compartments has assumed greater relevance in the pathophysiology of lean NASH. An expanded fat mass in the visceral adipose tissue (VAT) compartments has been observed in MONW subjects [9]. WC and WHR, as measures of central adiposity or VAT, show strong linear correlation with overall adiposity, as defined by BMI and also correlate more precisely with intra-abdominal fat, defined by abdominal MRI, in higher degrees of adiposity [22]. Therefore, WC has been incorporated into the



Fig. 2 Disease biology of 'lean NASH'

NASH Non-alcoholic Steatohepatitis; BMI Body Mass Index; WC Waist Circumference; VAT Visceral adipose Tissue; SAT Subcutaneous Adipose Tissue; DSAT Deep Subcutaneous Adipose Tissue; WAT White Adipose Tissue; TG Triglyceride; NEFA Non-Esterified Fatty Acid.

definition of MS to improve the biological relevance of the measurement. However, these anthropometric measures of overall and central adiposity lack uniformity in their precision and efficiency for identifying health hazards across varying degrees of adiposity [18]. Studies in non-obese subjects report a varying relationship between WC and progressive liver disease. A study in an occidental population found no association between NASH-related fibrosis and WC, although an association between WC and risk of having a NAFL is consistently observed across other ethnicities, including Asians [16].

NAFL and even NASH have since been reported in individuals who are stringently non-obese (applying both BMI and WC criteria) [12]. This indicates the existence of a subset of NASH subjects that either has NASH unassociated with MS or, more likely, has fatty liver disease in which fat compartmentalization and distribution at ectopic sites are not picked up by the anthropometric yardsticks used, i.e., BMI and WC. Moreover, fat tissue in the body is in a state of flux under environmental influences. It has been proposed that its compartmental redistribution to deep subcutaneous adipose tissue (DSAT), in contrast to superficial subcutaneous adipose tissue (SSAT), might be pathogenetically important, since DSAT is metabolically more active and is similar to VAT [19]. Thus, such differences in body composition may contribute to the relatively subtle association of adiposity with NASH in lean people (Fig. 2).

Delayed trigger to adipocyte expansion: an intuitive hypothesis for lean NASH

Recent research has shown that the size of adipocytes and their biological behavior are critical issues in the pathogenesis of MS [23]. Adipocytes set the tone of the metabolic and low-grade inflammatory state that occurs in MS and NASH [14]. There is an inter-individual variation in adipocyte size among lean and obese individuals [23]. Asian Indians have been shown to have larger adipocytes compared to Caucasians and other ethnic groups [10]. Furthermore, gene expression profiling of human adipocytes of different sizes from the same adipose tissue sample has identified that large adipocytes have a markedly higher gene expression than small adipocytes. The majority of these genes were immune related, often with important roles in the maintenance as well as regulation of cell structure, or with unknown functions [24]. In light of these, the functional plasticity and expandability of adipose tissue have become the subject of extensive research studying the pathogenesis of NASH. All individuals possess a maximum, but limited, capacity for adipose expansion, which is determined by both genetic and environmental factors. Once the adipose tissue expansion limit has been reached, it ceases to store energy efficiently, and lipids begin to accumulate in other tissues [23]. Such ectopic lipid accumulation in non-adipocyte cells results in lipotoxic insults that include IR, tissue damage, and inflammation.

Adipocyte turnover studies indicate that the overall size of the adipocyte mass is set at a higher level of equilibrium in childhood and adolescence in obese subjects, with turnover in adulthood similar to that in lean adults [23]. It is possible that the age of the switch to adipocyte mass expansion by either hypertrophy or hyperplasia may be critically different in classical vs. lean NASH. In developing nations, weight gain is mostly an adult phenomenon. In these developing countries where lean NASH is more prevalent, early life nutritional stress is often followed by

relative abundance in adulthood. Moreover, lifestyle changes classically associated with MS and NASH occur in adulthood in these lean individuals. This contrasts with the setting of the developed nations where the switch to adiposity occurs in childhood and adolescence [25]. Thus, a relatively late trigger to adipocyte expansion and meta-inflammatory perturbations may underlie the phenotypic differences between obese and lean NASH.

Genes, diet, and intestinal flora: lean NASH perspective

Available information on the genetics of NASH is heavily weighted in favor of an association with PNPLA3 variants. There is significant uniformity in the strength of this association across different races. On the other hand, variant alleles of APOC3 loci have been shown to address the ethnic-specific differences in NAFL. Although its association has been reported with NAFLD and IR in Asian Indians, this has subsequently not been replicated in other studies. Particularly concerning were the negative results from the Dallas Heart Study cohort, a population with a predominance of obesity [26, 27]. In addition, identification of FTO and LAMA-1 gene variants that have shown stronger genetic predisposition to diabetes, MS, and IR in non-obese subjects has raised the possibility of a variant genetic basis for lean NASH [28]. While genetic factors in lean NASH need to be delineated, dietary factors, particularly consumption of a 'more inflammatory diet' characterized by higher levels of cholesterol, transfatty acid, and carbohydrates including sucrose, by the Asians can lead to a deranged cellular energy balance and may contribute to NAFLD [29].

Apart from these genetic, dietary, and lifestyle influences, the resident intestinal flora seems to be another critical determinant in the genesis of NASH and MS. It plays an important role in substrate availability from the diet and modifies the host's metabolic milieu, immune function, and inflammation. Most relevantly, gut microbial 'enterotypes' have been demonstrated to change with the countries' progression from being socioeconomically developing to developed, and there are distinct differences in the composition of gut microbes with respect to microbial diversity, differential enrichment of microbial genes, and metabolic functions in obese and non-obese persons [30]. In addition to this complex pathophysiological interplay, the maternal nutritional status during the gestational period, low birth weight (LBW), and malnutrition in early life have been related to MS and its consequences in adult life. Given the prevalence of LBW to the extent of 23 %, growth retardation in young children to the extent of 60 %, and high prevalence of maternal malnutrition in developing countries like India, these features may also contribute to the genesis of the phenotype called 'lean NASH' [3].

'Lean NASH' in the present clinical perspective: issues in clinical diagnosis and assessment

'Lean NASH,' i.e., the presence of fatty liver in lean/non-obese subjects, is evolving as a clinical entity, and more information is needed before its characteristics, outcome, and management can be crystallized for guiding clinical case management. As of now, we should consider NASH in the differential diagnosis of unexplained liver disease even if the anthropometric parameters are within normal range or are subtly abnormal. Relevant clinical scenarios would include unexplained liver enzyme elevation and chronic hepatitis/chronic liver disease including hepatocellular carcinoma of unclear etiology, particularly in a setting of diabetic or impaired glucose tolerance. Metabolic abnormalities found in 'lean NASH' are similar to those seen in the classical phenotype, i.e., 'obese NASH,' and should be analyzed in detail. Standard diagnostic criteria, particularly the histology, management strategy, and surveillance protocol for NASH, are also applicable to lean subjects (Fig. 3). It needs to be emphasized that a stringent definition of leanness/non-obesity is to be adopted in future research protocols for identification of 'lean NASH' (Fig. 3). A number of noninvasive modalities including biomarkers have been evaluated and validated for the diagnosis and severity assessment of NAFLD/NASH, mostly in obese subjects [31, 32]. Different panels of markers include BMI or other anthropometric measurements to develop prediction models for the presence of NASH and presence of fibrosis in NASH [31–33]. In most such cases, BMI has been used as a categorical covariate and found to have predictive value above a definite cutoff value that indicates obesity. Hence, performance characteristics of such prediction models and biomarkers need to be evaluated specifically in non-obese subjects. A major departure, however, would emerge in the management of lean NASH. Behavioral therapy protocols for weight loss, one of the most impacting treatment modalities in classical obese NASH, are not relevant in this phenotype for obvious reasons. On the other hand, lean NASH is more biological, and the emerging therapeutic targets such as those acting by modifying insulin resistance, signaling of pathways of inflammation, and fibrosis as well as alterations in gut flora may find a wider role here.

Lean NASH: biologically distinct or a transitional nomenclature? Clinical implication

The lean NASH story is gradually being revealed. However, several issues remain unanswered. The most important concern is with the principles of nomenclature within syndromes where clinical dissimilarities exist despite biological similarities. It is relevant to raise the question as to whether it is epistemologically correct to classify subsets within a disease based on observed anthropometric parameters (e.g., BMI and



Fig. 3 Issues for diagnostic consideration of 'lean NASH'

Ethnicity specific cut-off values for anthropometric parameters are proposed by World Health Organisation as well as International Diabetes Federation [Ref No. 18]

WC in NAFLD/NASH). Such attempts are, however, commonplace in the evolution of nomenclature of defined entities in clinical sciences. Non-A-non-B hepatitis was the transitional coinage for a long time until the hepatitis C virus was cloned and demonstrated to be the elusive non-A-non-B agent. While IR unites the MS cluster and tries to provide uniformity concerning the genesis, significant divergence exists among the constituent phenotypes in terms of the strength of the association and biological principles. NAFLD and most importantly NASH already have an exclusionary component and a fair amount of arbitrariness (amount of alcohol intake) in its current name. It may be argued that adding another prefix that again relies on a probabilistic rather than putative or demonstrated mechanistic association would be adding further confusion and inaccuracy in understanding the disease. Until a uniformly acceptable pathophysiological and/or etiology-based classification emerges, the term "lean NASH" would continue to provide us an opportunity to ponder and refine this subset of fatty liver in non-obese people with potentially significant liver disease.

Conflict of interest Abhijit Chowdhury and Kausik Das declare that they have no conflict of interest.

Ethical standards This article does not contain any studies with human or animal subjects.

References

1. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37(4):917–923
2. Kim LJ, Nalls MA, Eiriksdottir G, Sigurdsson S, Launer LJ, Koster A, et al. AGES-Reykjavik Study Investigators. Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study. Obesity (Silver Spring) 2011;19(6):1265–1271
3. Misra A, Vikram NK. Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications. Nutrition 2004;20(5):482–491
4. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006;40(8):745–752
5. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164(19):2169–2175
6. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012;91(6):319–327
7. Margariti E, Deutsch M, Manolakopoulos S, Papatheodoridis GV. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterology 2012;25(1):45–51
8. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2224–2260
9. Ruderman NB, Schneider SH, Berchtold P. The "metabolically-obese," normal-weight individual. Am J Clin Nutr 1981;34(8):1617–21
10. Chandalia M, Lin P, Seenivasan T, Livingston EH, Snell PG, Grundy SM, et al. Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. PLoS One 2007;2(8):e812
11. Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci USA 2006;103(48):18273–18277
12. Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease Hepatology 2010;51:1593–1602
13. Phan-Hug F, Beckmann JS, Jacquemont S. Genetic testing in patients with obesity. Best Pract Res Clin Endocrinol Metab 2012;26(2):133–143

14. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444(7121):860–867
15. Troiano RP, Frongillo EA Jr, Sobal J, Levitsky DA. The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Relat Metab Disord 1996;20(1):63–75
16. Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol 2011;54(6):1244–1249
17. Wang ZM, Pierson RN Jr, Heymsfield SB. The five-level model: a new approach to organizing body-composition research. Am J Clin Nutr 1992;56(1):19–28
18. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363(9403):157–163
19. Kohli S, Sniderman AD, Tchernof A, Lear SA. Ethnic-specific differences in abdominal subcutaneous adipose tissue compartments. Obesity (Silver Spring) 2010;18(11):2177–2183
20. Chang Y, Ryu S, Sung E, Woo HY, Cho SI, Yoo SH, et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 2009;58(10):1419–1425
21. Tanaka S, Honda M, Wu B, Kazumi T. Clinical features of normal weight Japanese patients with type 2 diabetes who had formerly been obese. J Atheroscler Thromb 2011;18(2):115–121
22. Stevens J, McClain JE, Truesdale KP. Selection of measures in epidemiologic studies of the consequences of obesity. Int J Obes (Lond) 2008;32(Suppl 3):S60–S66
23. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, et al. Dynamics of fat cell turnover in humans. Nature 2008;453(7196):783–787
24. Jernås M, Palming J, Sjöholm K, Jennische E, Svensson PA, Gabrielsson BG, et al. Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB J 2006;20(9):1540–1542
25. Flegal KM, Troiano RP. Changes in the distribution of body mass index of adults and children in the US population. Int J Obes Relat Metab Disord 2000;24(7):807–818
26. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011;53(2):467–474
27. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010;362(12):1082–1089
28. Perry JR, Voight BF, Yengo L, Amin N, Dupuis J, Ganser M. Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS Genet 2012;8(5):e1002741
29. Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 2009;44(4):471–477
30. Shanahan F. The gut microbiota-a clinical perspective on lessons learned. Nat Rev Gastroenterol Hepatol 2012;9(10):609–614
31. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013;58(5):1007–1019
32. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008;134(6):1682–1698
33. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008;28(4):386–395